Novo Nordisk, Vivtex to Develop Obesity Drugs in Deal Valued at Up to $2.1 Billion

Core Insights - The pharmaceutical giant is entering a partnership with Vivtex to license drug-delivery technologies aimed at developing next-generation oral medications for obesity, diabetes, and related diseases [1] Group 1 - The collaboration focuses on enhancing drug-delivery systems to improve the efficacy of oral medications [1] - The targeted diseases include obesity and diabetes, which are significant health concerns globally [1] - This partnership may position the company to capture a larger market share in the growing sector of oral medications for chronic diseases [1]